PANews reported on November 27th that, according to Jinshi News, the Office of the United States Trade Representative announced on November 26th local time that it will extend the tariff exemptions imposed under Section 301 investigations concerning Chinese technology transfer and intellectual property issues until November 10th, 2026. The existing exemptions were originally scheduled to expire on November 29th of this year.PANews reported on November 27th that, according to Jinshi News, the Office of the United States Trade Representative announced on November 26th local time that it will extend the tariff exemptions imposed under Section 301 investigations concerning Chinese technology transfer and intellectual property issues until November 10th, 2026. The existing exemptions were originally scheduled to expire on November 29th of this year.

The United States will extend some tariff exemptions on Chinese goods until November 10, 2026.

2025/11/27 08:17

PANews reported on November 27th that, according to Jinshi News, the Office of the United States Trade Representative announced on November 26th local time that it will extend the tariff exemptions imposed under Section 301 investigations concerning Chinese technology transfer and intellectual property issues until November 10th, 2026. The existing exemptions were originally scheduled to expire on November 29th of this year.

Market Opportunity
Polytrade Logo
Polytrade Price(TRADE)
$0.06041
$0.06041$0.06041
+3.54%
USD
Polytrade (TRADE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.